
|Videos|November 17, 2022
Dr. Morris on how PSMA-PET imaging has “exploded” in the past year
Author(s)Urology Times staff
“As the PSMA-PET market for access has grown, the coverage has actually been better than we anticipated when it first launched,” says David Morris, MD.
Advertisement
David Morris, MD, Urology Associates, Nashville, TN, discusses how PSMA-PET imaging is revolutionizing prostate cancer care. “We all recognize it’s better than conventional imaging in terms of finding metastatic lesions and with that, it enables us to grow our potential patient based for targeted therapies.” says Morris.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5


















